Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Regenxbio Inc (NQ: RGNX ) 12.85 -0.43 (-3.24%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 499,882 Open 13.24 Bid (Size) 13.00 (1) Ask (Size) 13.98 (1) Prev. Close 13.28 Today's Range 12.68 - 13.53 52wk Range 10.49 - 28.80 Shares Outstanding 43,466,186 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Why Is Clearside Biomedical Stock Gaining Today? June 25, 2024 Clearside Biomedical pioneers suprachoroidal drug delivery for precise, effective treatment of retinal diseases. Oppenheimer rates CLSD Outperform with a $5 target, citing its innovative SCS... Via Benzinga 7 Biotech Stocks to Buy on the Dip: June 2024 June 24, 2024 With health being a top priority over wealth generation, these biotech stocks to buy on the dip enjoy a sound framework for speculation. Via InvestorPlace Performance YTD -29.93% -29.93% 1 Month +5.24% +5.24% 3 Month -20.24% -20.24% 6 Month -6.68% -6.68% 1 Year -29.90% -29.90% More News Read More FDA Approves Expanded Use For Sarepta's Rare Muscular Dystrophy Gene Therapy June 21, 2024 Via Benzinga Exposures Product Safety Sarepta Skyrockets After Nabbing A Broad Label For Its Duchenne Gene Therapy June 20, 2024 Via Investor's Business Daily Sarepta Jumps After Pfizer's Rival Gene Therapy Flops In Phase 3 Test June 13, 2024 Via Investor's Business Daily Exposures Product Safety Assessing Regenxbio: Insights From 4 Financial Analysts June 07, 2024 Via Benzinga Evaluating Regenxbio: Insights From 9 Financial Analysts May 15, 2024 Via Benzinga Where Regenxbio Stands With Analysts April 12, 2024 Via Benzinga Goldman Sachs Optimistic About Regenxbio's Gene Therapy Pipeline, Sees Over 160% Upside June 07, 2024 Via Benzinga RGNX Stock Earnings: Regenxbio Misses EPS, Misses Revenue for Q1 2024 May 08, 2024 Via InvestorPlace 12 Health Care Stocks Moving In Monday's After-Market Session March 25, 2024 Via Benzinga Does This 1 New Threat Make Sarepta Therapeutics Stock Worth Selling? March 13, 2024 Via The Motley Fool This Gene Therapy Player Duchenne Data Is Impressive, Analyst Upgrades REGENXBIO March 08, 2024 Via Benzinga Beyond The Numbers: 4 Analysts Discuss Regenxbio Stock March 06, 2024 Via Benzinga Regenxbio: Q4 Earnings Insights February 27, 2024 Via Benzinga Earnings Scheduled For February 27, 2024 February 27, 2024 Via Benzinga A Preview Of Regenxbio's Earnings February 26, 2024 Via Benzinga REGENXBIO's Muscle Wasting Disorder Drug Shows Strength, Improved Motor Function, Stock Soars March 05, 2024 Via Benzinga 12 Health Care Stocks Moving In Tuesday's Pre-Market Session March 05, 2024 Via Benzinga Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session March 01, 2024 Via Benzinga Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday March 01, 2024 Via Benzinga Topics Stocks Exposures US Equities Gene Therapy Player REGENXBIO's RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst February 12, 2024 Via Benzinga The One-Minute Market Report - Sunday, Feb. 11 February 11, 2024 Via Talk Markets Jim Cramer Says Investors Should Look Beyond Apple, Meta And Other Magnificent 7 Stocks: 'You Might Be Missing Out On Some Huge Gains' February 08, 2024 Via Benzinga Why Is Blindness Focused-Adverum Biotechnologies Stock Trading Lower Today? February 08, 2024 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
